Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExp ...
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production ...
Rising demand for recombinant proteins, automation-ready cloning workflows, and AI-integrated molecular biology kits accelerates market growth at a CAGR of 10.68%.Austin, United States, March 25, 2026 ...
In academic and industrial protein research, speed, accuracy, and accessibility are essential. After purifying proteins using ...
France’s Saint‑Julien site adds a bioprocess development suite for upstream/downstream scale-up of recombinant proteins, ...
After Decades of Global Failures, Kraig Poised to Deliver First High-Performance Recombinant Breakthrough DENVER, ...
Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO ...
For research scientists and laboratory professionals navigating increasingly complex experimental challenges, access to ...
Can healthy dividends continue from CSL? The post Here's the dividend forecast out to 2030 for CSL shares appeared first on The Motley Fool Australia.
As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...
Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results